SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property associated primarily with the MUSE™ endoscopic system from Xylo Technologies Ltd. The MUSE™ system is a single-use, innovative device designed for transoral fundoplication, a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). As consideration for the acquired assets, SciSparc will issue to Xylo ordinary shares representing 19.99% of its issued and outstanding share capital as of the closing date, set for March 8, 2026, or may elect to issue pre-funded warrants in lieu of shares. SciSparc plans to begin commercializing the technologies immediately after closing, aiming to replicate Xylo's successful licensing model in Greater China by pursuing exclusive partnerships with regional distributors in North America, Europe, and Latin America. The transaction is subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624676-en) on January 13, 2026, and is solely responsible for the information contained therein.